# US 10,479,834 B2 · Fc receptor antibodies and methods of use thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,479,834 B2 - Document ID: US10479834B2 - Status: Granted - Kind: B2 - Application number: 15/830,998 - Filed: 2017-12-04 - Published: 2018-10-25 - Granted: 2019-11-19 - Earliest claimed: 2011-06-02 - Assignees: Dyax Corp. - Applicants: Dyax Corp. - Inventors: Daniel J. Sexton; Christopher TenHoor; Malini Viswanathan - Web page: https://patentgrep.com/patent/US10479834B2 ## CPC - C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)} - A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines} - A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy - A61K 49/0002: {General or multifunctional contrast agents, e.g. chelated agents} - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 37/00: Drugs for immunological or allergic disorders - A61P 37/02: Immunomodulators - A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - G01N 33/6854: {Immunoglobulins} - A61K 2039/505: {comprising antibodies} - C07K 2317/565: Complementarity determining region [CDR] - C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The disclosure relates to antibodies that bind FcRn and methods of using these antibodies. ## Claims ### Claim 1 An isolated anti-neonatal Fc receptor (FcRn) antibody comprising a light chain variable region (VL) and a heavy chain variable region (VH), wherein the antibody binds to human FcRn; wherein the VL comprises: (i) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:14; (ii) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:15; and (iii) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:12 or SEQ ID NO:13; and wherein the VH comprises: (i) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:22; (ii) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:23; and (iii) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:24. ### Claim 2 (depends on 1) The isolated antibody of claim 1, wherein the VL of the isolated antibody comprises the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 11. ### Claim 3 (depends on 1) The isolated antibody of claim 1, wherein the VH of the isolated antibody comprises the amino acid sequence of SEQ ID NO: 9. ### Claim 4 (depends on 1) The isolated antibody of claim 1, wherein the isolated antibody is a human or humanized antibody or is non-immunogenic in a human. ### Claim 5 (depends on 4) The isolated antibody of claim 4, wherein the isolated antibody comprises a human antibody framework region. ### Claim 6 (depends on 1) The isolated antibody of claim 1, wherein the isolated antibody is a murine antibody. ### Claim 7 (depends on 1) The isolated antibody of claim 1, wherein the isolated antibody is chimeric. ### Claim 8 (depends on 1) The isolated antibody of claim 1, wherein the isolated antibody is a full-length antibody. ### Claim 9 (depends on 1) The isolated antibody of claim 1, wherein the isolated antibody is selected from the group consisting of Fab, F(ab)′2, Fv, and scFv. ### Claim 10 (depends on 1) A pharmaceutical composition comprising the isolated antibody of claim 1 and a pharmaceutically acceptable carrier. ### Claim 11 (depends on 1) A method of detecting an FcRn in a sample or in a subject, the method comprising: contacting the sample with the isolated antibody of claim 1, and detecting an interaction between the isolated antibody and the FcRn if present. ### Claim 12 (depends on 1) A method of modulating the half-life or level of a circulating IgG in a subject, the method comprising administering to the subject the isolated antibody of claim 1 in an amount effective to modulate the half-life or level of a circulating IgG in the subject. ### Claim 13 (depends on 12) The method of claim 12, wherein the subject has an autoimmune disease or an inflammatory disorder. ### Claim 14 (depends on 12) The method of claim 12, wherein the subject contains an unwanted IgG in the bloodstream. ### Claim 15 (depends on 14) The method of claim 14, wherein the unwanted IgG is an anti-human leukocyte antigen (HLA) IgG antibody. ### Claim 16 (depends on 15) The method of claim 15, wherein the subject has received an organ transplant.